In the article, “Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial” by Antman et al that appeared online on March 4, 2002, as a Rapid Track (Circulation. 2002;105:r27–r34) and in the April 9, 2002, issue of the journal (Circulation. 2002;105:1642–1649), an error appeared in Figure 2.
The inset portion in the top right corner of Figure 2 shows the following values for the 30-day mortality, recurrent infarction, and composite death/MI rates for the unfractionated heparin (UFH) and enoxaparin (ENOX) groups, respectively: 3.1%, 7.5%, and 10.7% versus 3.1%, 1.9%, and 5.0%. The P value for comparison of the recurrent infarction rate was shown as 0.002 and that for the composite death/MI rate as 0.012.
The correct numbers are as follows: For the UFH group, 30-day mortality rate was 3.1%, recurrent infarction rate was 8.2%, and the composite rate was 11.3%. For the ENOX group, 30-day mortality rate was 3.1%, recurrent infarction rate was 1.8%, and the composite rate was 4.9%. The P value for comparison of the recurrent infarction rates was 0.002 and that for comparison of the composite death/MI rate was 0.01.